# Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

> **NCT05763875** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 350 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran
- **DRUG:** Ezetimibe
- **DRUG:** Matching Placebo for Inclisiran
- **DRUG:** Matching Placebo for Ezetimibe

## Key facts

- **NCT ID:** NCT05763875
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-15
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763875, "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05763875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*